Stryker Corporation (SYK)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $bn | 14 | 17 | 18 | 20 | 23 | 25 | 26 | 27 |
| Operating profit | $bn | 5 | 6 | ||||||
| Net profit | $bn | 2 | 2 | 2 | 3 | 3 | 3 | 4 | 6 |
| EPS reported | $ | 8.40 | 9.65 | ||||||
| Operating cashflow per share | $ | 13.20 | 14.41 | ||||||
| Capex per share | $ | 1.99 | 2.15 | ||||||
| FCF per share | $ | 11.21 | 12.26 | ||||||
| Free cash flow | $bn | 4 | 5 | ||||||
| Net debt | $bn | 12 | 11 | ||||||
| Book value equity | $bn | 22 | 24 | ||||||
| Book value per share | $ | 58.66 | 62.15 | ||||||
| Number of shares | m | 382.2 | 386 | ||||||
| DPS (TTM paid) | $ | 3.40 | 4.36 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 41.84 | 28.22 | ||||||
| P/B LTM | x | 5.99 | 5.60 | ||||||
| P/S LTM | x | 5.35 | 5.20 | ||||||
| P/FCF LTM | x | 31.36 | 28.57 | ||||||
| EV/EBITDA LTM | x | 23.23 | 23.45 | ||||||
| EV/Sales LTM | x | 5.84 | 5.54 | ||||||
| Earnings Yield LTM | % | +2.39% | +3.54% | ||||||
| FCF Yield | % | +3.19% | +3.50% | ||||||
| Quality | |||||||||
| ROE | % | +14.48% | +16.36% | ||||||
| ROIC | % | +8.53% | +9.82% | ||||||
| Operating margin | % | +19.47% | +22.03% | ||||||
| Gross margin | % | +63.96% | +65.17% | ||||||
| FCF/Sales | % | +17.05% | +18.20% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +8.25% | +24.36% | ||||||
| Sales Growth YoY | % | +11.16% | +14.35% | ||||||
| Net Income Growth YoY | % | +8.45% | +24.59% | ||||||
| FCF Growth | % | +22.83% | +34.84% | ||||||
| Operating Profit Growth | % | -3.40% | +12.45% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +0.96% | +1.01% | ||||||
| Dividend Growth | % | +4.94% | +34.57% | ||||||
| Payout Ratio | % | +39.99% | +35.32% | ||||||
| FCF/Debt | x | 0.26 | 0.31 | ||||||
| Net Debt/EBITDA | x | 1.96 | 1.85 | ||||||
| EBIT/Net interest | x | 8.05 | 8.30 | ||||||
| Net debt/market cap | % | +11.92% | +11.35% | ||||||
| Net debt/Equity | x | 0.53 | 0.48 | ||||||
| Gross debt/equity | x | 0.73 | 0.62 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free